We have only begun to harness the power of social media as it pertains to toxicology.
Phoenix, Arizona (PRWEB) February 27, 2014
The Journal of Medical Toxicology (JMT) begins its 10th year of publication with several new articles in the March issue (Volume 10, Issue 1) that reflect its international reach and commitment to publishing cutting-edge work relevant to clinicians and researchers. An important study in this new issue that will undoubtedly generate continued discussion and future work is “Complications Following Antidotal Use of Intravenous Lipid Emulsion Therapy (ILE).” This multi-center effort is one of the first to examine potential complications associated with the antidote called “miracle fat” by some clinicians. According to lead author Dr. Michael Levine, there is still “limited experience with antidotal use of ILE” despite unconditional enthusiasm by some clinicians. Levine and co-authors suggest a “risk–benefit analysis should be performed for each patient” being considered to receive this antidote. Additional cutting-edge work examining the clinical role of ILE and other new antidotes can be found in the abstracts from ACMT’s 2014 Annual Scientific Meeting, also published in this issue. Many of those abstracts offer an early preview of future publications, some of which will ultimately prove to be standard-setting.
Several reports in the March issue also highlight technology and its evolving role in clinical practice. In a commentary relevant to all 21st century healthcare providers, editorial board member Dr. Navneet Cheema examines the role of Twitter and social media in clinical practice and public health. She writes, “We have only begun to harness the power of social media as it pertains to toxicology. It is a vast, underutilized tool that has the potential to transform, expand, and improve our field.” Further technology articles include a study by Dr. Jeff Lapoint and colleagues who study the veracity and usefulness of electronic pharmacopeia available on most smartphones, and important advice from Dr. Fred Fung who offers guidelines on introducing telemedicine to centers that do not have a bedside medical toxicologist.
These articles, and many others published in the March issue of JMT, confirm editor-in-chief Leslie Dye’s reflections that “ “the high quality and wide reach of the manuscripts in our Journal highlight the successes of the past decade, and bespeak an even brighter future for the next 10 years!”
ACMT is a professional, nonprofit association of physicians with recognized expertise in medical toxicology. The College is dedicated to advancing the science and practice of medical toxicology through a variety of activities.